Patients with advanced chronic kidney disease (CKD) show decreased hemoglobin levels. We aimed to verify the changes of red blood cell (RBC) number according to glomerular filtration rate (GFR) levels and its influence on the clinical outcome. With the data from routine health checkups of 114,496 adults, we grouped the subjects according to quartile levels of RBC number in each gender. Mortality data were from the National Statistical Office. RBC number was increased with decreasing GFR and/or the presence of a component of metabolic syndrome (MS) in subjects with GFR ≥ 50 ml/min/1.73 m 2 . The estimated mean RBC number of subjects with GFR 89-50 ml/min/1.73 m 2 was higher compared to those with GFR ≥ 100 ml/min/1.73 m 2 by ANCOVA. In men, the death rate was the highest in the 1 st quartile group (1Q) of RBC number (1.22%), followed by the 2 nd quartile group (2Q, 0.42%), the 3 rd quartile group (3Q, 0.39%), and the 4 th quartile group (4Q, 0.29%) (p < 0.001). The hazard ratio (HR) of death in 2Q, 3Q and 4Q was 0.446, 0.580, and 0.440, respectively, compared to 1Q (p < 0.001). Among men in 1Q group, subjects with hemoglobin < 14.0 g/dL showed higher mortality rate than those with hemoglobin 14.0-14.9 g/dL or ≥ 15.0 g/dL (2.3% : 0.8% : 1.1%, respectively, p < 0.001). In conclusion, the RBC number was increased according to declines of GFR in the range of GFR ≥ 50 ml/min/1.73 m 2 and was an important risk factor for mortality.
Patients with advanced chronic kidney disease (CKD) show a decreased hemoglobin level, primarily as a consequence of reduced renal production of erythropoietin (EPO) (Remuzzi et al. 2000) . The National Health and Nutrition Examinational Survey III in USA reported that the prevalence of anemia is increased in subjects with glomerular filtration rate (GFR) < 60 ml/min/1.73 m 2 (National Kidney Foundation 2000). Additionally, a cohort study including subjects who had CKD stages 3 through 5 showed that the estimated GFR threshold level to detect complications was 44 ml/min/1.73m 2 (Moranne et al. 2009 ). However, we previously reported that the hemoglobin concentration was slightly increased across small declines in GFR and the presence of cardio-renal risk factors in early CKD stage (Oh et al. 2012) . We suggested that increased renal hypoxia presented ahead of apparent CKD, as reported in early diabetic kidney and angiotensin II-related hypertension (HTN) (Pollock et al. 2008; Lerman et al. 2009 ), might stimulate the protein level of hypoxia-inducible factor (HIF) to induce transcription of EPO and other cellular responses to adopt hypoxia. Donnelly proposed that the kidney detects changes in tissue oxygen content for EPO production (Dunn 2007) . When renal function decreases, the macula densa cells respond to the change in luminal delivery of chloride, leading to the release of renin and angiotensin II (PetiPeterdi et al. 2010) . Angiotensin II increases oxygen consumption, decreases the oxygen supply to the juxtamedullary area of the kidney, and induces responses of HIF and EPO (Dunn 2007; Deng et al. 2009 ).
In erythropoiesis, EPO is the central hormone which cannot be replaced by other growth factors at the stage of late colony-forming unit-erythroid, but, beyond this stage of erythroid development, EPO is not important for the terminal stages of differentiation (Lin 2009 ). To produce hemoglobin, the other regulations for iron, heme, and globin metabolism are required. Recently, hepcidin has been reported as the major regulator of baseline iron homeostasis (Ganz 2007) . Also, heme synthesis regulates the supply of iron (Koury 2004 ) and the synthesis of globin (Ponka 1997) , which are needed to form hemoglobin effectively. Therefore, the red blood cell (RBC) number might be a more direct marker of EPO level stimulated by tissue hypoxia than the hemoglobin level is.
We analyzed the data from routine health checkup with various GFRs to determine the relationships firstly among RBC number, GFR, and a cardio-renal risk factor of metabolic syndrome (MS), and secondly, among RBC number, the hemoglobin level, and all-cause mortality rate.
Methods

Participants
We selected adult participants aged ≥ 20 years who had undergone a voluntary routine health checkup from Jan 2003 to April 2009. The subjects answered questions about smoking and drinking habits, medical history of diabetes mellitus (DM), HTN, and medication for HTN and DM prior to the examination. This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of the Seoul National University Bundang Hospital (H-1003-095-104).
Measurements and definitions
The subjects arrived at hospital after a 12-hr overnight fast and underwent blood and urine tests. Complete blood cell counts, including RBC number, hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) were measured and calculated by a Sysmex XE-2100 Hematology Analyzer (Sysmex, Kobe, Japan) (Nakul-Aquaronne et al. 2003) . Serum creatinine was measured by the alkaline picrate Jaffe kinetic method using an automatic analyzer (Toshiba 200FR, Tokyo, Japan). Serum creatinine levels were calibrated to an assay traceable to isotope dilution mass spectrometry (IDMS) (Roche diagnostics) (Levey et al. 2006) . GFR was calculated using the Modification of Diet in Renal Disease study equation (Levey et al. 2006) . Proteinuria was determined by urine dipstick test, using an automated urine analyzer CLINITEK ATLAS (Siemens Healthcare Diagnostics, Deerfield, IL). The components of MS were defined by the National Cholesterol Education Program ATP III (Grundy et al. 2005) .
Outcomes
We joined the mortality data of the National Statistical Office from January 2003 to December 2009 to our data set using each individual's unique identification number. Among 114,500 candidates, mortality data were obtained for 114,496 subjects, who were thus included in this analysis. There were 495 deaths overall, 122 for 52,966 women (0.203%), and 366 for 61,530 men (0.595%), during an average follow-up period of 39.8 ± 20.7 months.
Statistical analyses
All analyses were performed using SPSS software (SPSS version 18.0; Chicago, IL). Data are presented as the mean ± s.d. for continuous variables and as a proportion for categorical variables.
Differences in continuous variables were analyzed by one-way analysis of variance tests (ANOVA) or Student t-test according to the number of subgroups and by chi-square tests in categorical variables. We analyzed independent factors related to RBC number by multiple linear regression analysis. Analysis of covariance (ANCOVA) was used for adjusting independent factors related to RBC number according to GFR (GFR group) and the number of MS components (MS Group). In our previous report (Oh et al. 2012) , we found the hemoglobin level was highest in GFR 50-59 ml/min/1.73 m 2 . As a continuum of previous research, we also classified GFR into seven groups as in the previous report: Group 1, GFR ≥ 100; 2, GFR 90-99; 3, GFR 80-89; 4, GFR 70-79; 5, GFR 60-69; 6, GFR 50-59 and 7, GFR < 50 mL/min/1.73 m 2 . We compared the cumulative incidence of all-cause mortality among the participants categorized into four quartile groups, with the 1 st to 4 th quartile groups of RBC number being termed 1Q to 4Q, respectively, according to baseline RBC number (RBC group) by log-rank test. Cox's proportional hazard analysis was used to estimate the hazard ratio (HR) for mortality, adjusted with the risk factors in each gender. We searched for any interaction between the RBC groups and the other risk factors and repeated the analysis in subgroups categorized by age, GFR, and the presence or absence of an MS component. We analyzed the distribution of hemoglobin level in the RBC groups and the relationship between hemoglobin level (hemoglobin group) and the risk of mortality in each RBC group. P-values were reported with 0.05 taken as the level of statistical significance.
Results
The RBC number according to GFR group and MS group
The proportion of subjects included in GFR groups 1-7 was 20.38%, 17.94%, 23.74%, 23.51%, 11.59%, 2.30%, and 0.52%, respectively. In men, the estimated mean RBC numbers of GFR Group 2 (p = 0.006) and Groups 3-6 ( p < 0.001) were higher compared to that of Group 1 using ANCOVA. The estimated mean RBC number in GFR Groups 1-7 was 4. 12 cells/L, respectively. The RBC number in each GFR group increased with increasing number of MS components. The mean RBC number in the MS group with any MS components was higher than that of the MS group without an MS component in all GFR groups in both genders (Fig. 1) .
The basal characteristics of the RBC groups
The 4Q group showed significantly younger age, higher frequency of HTN and proteinuria, higher levels of BMI, number of MS components, systolic blood pressure (SBP), diastolic blood pressure (DBP), serum protein, serum albumin, total cholesterol, triglyceride, uric acid, and hemoglobin, lower frequencies of positivity in HBsAg and anti-HCV antibody and hematuria, and lower levels of MCV and MCH, compared to the other three RBC groups in men (Table 1 ). The differences among the RBC groups were less evident in women than in men ( Table 2 ).
The mortality of RBC groups in men
In men, the death rate was 1.22% (195/15,866), 0.42%
(63/14,875), 0.39% (67/16,812), and 0.29% (41/13,977) in RBC groups 1Q-4Q, respectively ( p < 0.001). The survival rate in 1Q was the worst ( p < 0.001, Fig. 2 ). The relationship between RBC group and mortality exhibited similar results after excluding data from men with extremely low hemoglobin level less than 12 g/dL (data not shown). With A. Mean RBC number in GFR groups 2-7 was different compared to GFR group 1 (P ≤ 0.017). B. Mean RBC number in GFR groups 3-7 was different compared to GFR group 1 (P ≤ 0.031). C. *P ≤ 0.001, mean RBC number of GFR groups 3-5 and 7 was different compared to GFR group 1 in patients with no MS component. **P < 0.001, mean RBC number of GFR groups 3-5 and 7 was different compared to GFR group 1 in patients with 1 MS component. † P ≤ 0.011, mean RBC number of GFR groups 3-5 and 7 was different compared to GFR group 1 in patients with 2 MS components.
‡ P ≤ 0.021, mean RBC number of GFR groups 3, 5 and 7 was different compared to GFR group 1 in patients with more than 3 MS components. Mean RBC number of 2 and ≥ 3 components was different compared to no MS component in all GFR groups (P < 0.001). Mean RBC number of 1 component was different compared to no MS component in GFR < 90 (P ≤ 0.014). D. *P < 0.001, mean RBC number of GFR groups 4-6 was different compared to GFR group 1 in patients with no MS component. **P < 0.001, mean RBC number of GFR groups 4-7 was different compared to GFR group 1 in patients with 1 MS component. † P ≤ 0.003, mean RBC number of GFR groups 4-6 was different compared to GFR group 1 in patients with 2 MS components. † † P < 0.001, mean RBC number of GFR < 50 was different compared to GFR >100 in patients with more than 3 MS components. Mean RBC number of ≥ 3 MS components was different compared to no MS component within GFR > 50 (P < 0.001), mean RBC number of 2 MS components was different compared to no MS component within GFR 50-89 (P < 0.001), and mean RBC number of 1 MS component was different compared to no MS component within GFR 60-89 (P ≤ 0.001). Cox's proportional hazard model, the RBC group was a risk factor for mortality in the fully adjusted model (Table 3 ). The HR of death was 0.446 (95% CI; 0.317-0.629), 0.580 (95% CI; 0.419-0.803), and 0.440 (95% CI; 0.289-0.668) in 2Q, 3Q and 4Q, respectively, compared to 1Q ( p for trend < 0.001). The subgroups were categorized with the criteria of age (50 years), GFR (60 ml/min/1.73 m 2 ), and presence of an MS component. There was no difference in survival among the RBC groups in subjects aged < 50 years or with GFR < 60 ml/min/1.73 m 2 (Table 3 ). The RBC group was an independent risk factor for mortality in subjects without an MS component but the Wald value of HR, which indicates the contributory priority of a parameter in the model, was lower than that of the model, including subjects with any number of MS components (9.112 vs. 23.616). The significance of RBC group on mortality was evident in subjects with GFR ≥ 60 ml/min/1.73 m 2 and with the presence of an MS component ( p < 0.007, Table 3 ).
The distribution of RBC indexes and the influence of hemoglobin level on mortality in each RBC group among men
The range of hemoglobin was wide in all RBC groups, including 1Q, although its mean value was the lowest in 1Q (Fig. 3) . The values of MCV and MCH increased with increasing hemoglobin level in each RBC group. The RBC groups were categorized with hemoglobin criteria of 14.0, 15.0, 16.0, and 17.0 g/dL. In 1Q, subjects with hemoglobin < 14.0 g/dL showed worse mortality rate than those with hemoglobin 14.0-14.9 g/dL or ≥ 15.0 g/dL (2.3% : 0.8% :
1.1%, p < 0.001). By Cox's model, the hemoglobin level < 14.0 g/dL in 1Q also showed a worse prognosis than that in the other hemoglobin groups ( p = 0.001, Fig. 4 ). The subjects with hemoglobin ≥ 15.0 g/dL showed a lower survival rate than those with hemoglobin 14.0-14.9 g/dL, but the difference was not significant. In the other RBC groups, the hemoglobin level did not affect the mortality.
The mortality of RBC group in women
In women, the death rate was 0.34% (45/13,147), 0.16% (21/13,214), 0.21% (29/13,672), and 0.21% (27/12,923) in RBC groups 1Q-4Q, respectively ( p = 0.014). The survival rate in 1Q was the worst ( p = 0.023, Fig. 5 ) but the trend of mortality was not consistent with the change of RBC number. We analyzed the interaction between factors related to mortality and the factor of the RBC group in women and found that the factors of age and serum levels of HDL-cholesterol and albumin showed a correlation with the RBC group. If the interaction variable of age*RBC group or HDL-cholesterol*RBC group was included in Cox's model, the significance of the RBC group was lost (data not shown).
Discussion
The study demonstrated that the RBC number increased with a small decrease of GFR and/or the presence of an MS component in subjects with GFR ≥ 50 ml/ min/1.73 m 2 . The RBC number was an independent risk factor for mortality in men, and this link was more evident in men with GFR ≥ 60 ml/min/1.73 m 2 and/or any MS components. Among men in 1Q, a low hemoglobin level was an important risk for mortality.
During erythropoiesis, many growth factors coordinate to commit pluripotent hematopoietic stem cells to the erythroid cell lineage and then to erythroid progenitor/burstforming unit-erythroid (Lin 2009 ). However, starting at the late CFU-E stage, an absolute requirement for EPO arises that cannot be replaced by other growth factors, thus rendering EPO the central hormone for erythropoiesis (Lin In men with GFR 60 or more and without MS component
In men with GFR 60 or more and with one or more MS component *Fully adjusted with age, SBP, DBP, diabetes mellitus, hypertension, BMI, HBsAg, anti-HCV antibody, AST, ALT, cholesterol, HDL-cholesterol, glucose, uric acid, GFR, Urine protein by dipstick test. *Groups compared to 1 st quartile group, MS component: component of metabolic syndrome defined by National Cholesterol Education Program ATP III. The RBC group was not a risk factor to mortality in subgroup with GFR less than 60 ml/min/1.73m 2 and with or without component of metabolic syndrome (data not shown). st quartile group of RBC in men. The subgroup with hemoglobin less than 14.0 g/dL showed the worst survival rate, analyzed by Cox's hazard proportional analysis adjusted with risk factors for mortality. The subgroup with hemoglobin 15.0 g/dL or more showed worse survival rate than the subgroup with hemoglobin 14.0-14.9 g/dL, although the difference was not significant.
2009
). EPO acts on erythroid progenitor cells to prevent apoptosis and stimulate their proliferation and maturation (Fisher 2003) . To produce hemoglobin, additional regulations for iron, heme, and globin metabolism are required. For example, hepcidin, as a regulator of iron metabolism, is reported to have a negative relationship with hemoglobin concentration in non-dialysis CKD patients (Uehata et al. 2012) . Among RBC indexes, MCV and RBC mass are reportedly more closely related to EPO administration than hemoglobin is (Fazlibegović et al. 2006) . Treatment with EPO increased the number of erythroid cells and MCV (Papayannopoulou et al. 1972) . Therefore, the response of EPO is represented more effectively by RBC number rather than by hemoglobin concentration. In this report, hemoglobin concentration showed a wide distribution regardless of RBC number. The hemoglobin concentration in 1Q was distributed up to 18.7 g/dL, which was almost the highest level in 4Q quartile group. In a certain RBC group, the higher hemoglobin was related to a higher MCV and MCH and, in a certain hemoglobin level, the higher RBC number was related to a lower MCV and MCH, which was consistent with previously reported data (Hawkey et al. 1991) . Hemoglobin showed a weaker relationship with RBC number compared to MCV and MCH, in agreement with another report (Tibblin et al. 1979) .
The elevation of RBC number and MCV associated with a minor decline of GFR and an increment in the number of MS components may have resulted from the increase of renal hypoxia aggravated by pre-existing conditions, such as angiotensin II activation (Peti-Peterdi et al. 2010) or accompanied atherosclerosis (Hultén 2009; Bitto et al. 2010) . In early research about EPO, normal and CKD subjects exhibited an increase of EPO and hematocrit according to the decrease of creatinine clearance (Ccr) (Radtke et al. 1979 ). The hematocrit level of CKD patients was slightly higher with a decrease of Ccr from 90 to about 45 ml/min, although this was not notified by the authors (Radtke et al. 1979 ). In addition, the serum EPO level in CKD patients was higher as Ccr was decreased from 90 to 30 ml/min and the EPO level of CKD patients with Ccr 90-30 ml/min was higher than that in healthy normal controls. Recently, the NephroTest study group reported an absence of any relationship between EPO concentration and measured GFR with 51 Cr-EDTA in patients without anemia and increased EPO level in patients with anemia and GFR ≥ 30 ml/min/1.73 m 2 (Mercadal et al. 2012) . However, one figure of the study also revealed a slight but significant increase in the median EPO level with the decrease of GFR in patients with GFR ≥ 30 ml/min/1.73 m 2 . The relationship between measured GFR and EPO was not significant with the regression analysis for any of the patients across all ranges of GFR, because the EPO level was variable in patients with GFR less than 30 ml/min/1.73 m 2 . The EPO level of patients with a cardio-renal risk factor, such as high BMI and DM, was 22-55% higher than patients without any risk factor (Mercadal et al. 2012) . This was consistent with our findings of increased RBC number and MCV with a small decrease of GFR and with the presence of a cardiorenal risk factor, such as an MS component.
Data have been reported in the literature about the relationship between hemoglobin and mortality in chronic heart failure (CHF) patients with CKD (Go et al. 2006) , patients under dialysis (Levin et al. 2006) , stroke patients with CKD (Del Fabbro et al. 2010) , and CKD patients (Mann 1999) . In CHF patients, hemoglobin levels of 13 g/ dL and 17 g/dL were turning points for mortality increment, which is similar to our results that men with hemoglobin less than 14 g/dL in 1Q showed a higher mortality rate and men with hemoglobin ≥ 15 g/dL showed a slightly higher mortality than subjects with hemoglobin 14-14.9 g/dL, P-value by Log rank test was 0.023. although these differences were not significant. The lower hemoglobin level may have been related to hemodynamic compensations, resulting in stress of ventricular function and increased mortality risk (Duke 1969) . The influence of RBC number and hemoglobin on mortality increased in the population with a mild decrease of GFR and the presence of an MS component. This suggests the importance of correcting anemia in patients with a cardio-renal risk factor, although the appropriate hemoglobin level has not yet been defined. In our data, the hemoglobin level did not estimate the outcome consistently if the data were not analyzed with consideration for the RBC mass. The production of RBC and hemoglobin is not a single pathway driven by growth factors, but is also related to iron, heme, and globin metabolism (Lin 2009 ). The mortality rate was dependent on the RBC number and the hemoglobin level. Unlike in men, the RBC number and hemoglobin level were not correlated with mortality in women. This was partially attributed to factors of age and serum HDL-cholesterol level, which had a significant interaction with the RBC number to predict mortality in women.
There are three limitations in the present study. Firstly, the estimated GFR could not represent the real value, especially in the normal range of GFR, although we used the IDMS-traceable creatinine to calculate GFR, which is a more accurate method to measure creatinine than the classical or modified Jaffe reaction. Secondly, we did not measure the EPO level to support our assumption of increased hypoxic stimuli according to the decrease of GFR and the presence of an MS component. According to previous reports on the changes of EPO level along with GFR change or the presence of obesity and DM, our assumption of a relationship between EPO, RBC mass, GFR, and cardio-renal risk factors is reasonable. Thirdly, we could not exclude other causes of anemia such as iron deficiency or vitamin deficiency, although the population characteristics, such as large sample size and generally healthy subjects, might compensate for this defect.
In conclusion, the RBC number was well correlated with GFR and the presence of an MS component, and was an important risk factor for mortality, especially in 1Q RBC group with lower hemoglobin level in men. Finally, we postulated that a hypoxic stress to increase the EPO response may have influenced the increase in the RBC number accompanied with the small decrease of GFR and the presence of a typical cardio-renal risk factor in men with GFR ≥ 50 ml/min/1.73 m 2 .
